Research programme: cancer vaccines - aVaxziPen/Unknown company
Latest Information Update: 28 Oct 2024
At a glance
- Originator Enesi Pharma
- Developer aVaxziPen
- Class Antineoplastics; Cancer vaccines; DNA vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for research development in Cancer in United Kingdom (Transdermal)
- 12 Sep 2020 Enesi Pharma collaborates with an undisclosed immunotherapy company to develop Cancer vaccine (Enesi Pharma pipeline, September 2020)
- 09 Sep 2020 Early research in Cancer in United Kingdom (Transdermal) (Enesi Pharma pipeline, September 2020)